Member spotlight: meet Abzena

Nicole Wakes.png

Nicole Wakes is currently the Senior Director of Cell Line Development at Abzena, a role that sees her deeply involved in the complexities of cell biology and bioproduction. In this blog, we delve into the world of Abzena through the lens of Nicole Wakes, exploring her journey, the company's ambitions, and her perspectives on the burgeoning UK life sciences sector.


Tell us about your company and ambitions?

Abzena has a focus on bioconjugates and biologics. We aim to push the development of novel treatments forward at every stage, from discovery through to commercial launch. We tailor our strategy and customer experience to each project, developing and implementing innovative solutions. This enables biotech and biopharma companies to realize the full potential of their investment in human health.

We operate globally with facilities in San Diego, California; Bristol, Pennsylvania; and Cambridge, UK. In my department, we focus on the early stages of our customer projects, working with a variety of clients, from academics to large pharma, to ensure the safety and feasibility of the products.

What is your company’s biggest achievement so far?

Our most notable accomplishment lies in our ability to establish significant partnerships with leaders in the biotech and biopharma companies. Our collaborations have enabled us to be at the crux of groundbreaking science, where we play an instrumental role in transforming novel concepts into tangible treatments. The transition from a scientific concept to a clinical application is complex and challenging. Abzena, over its years of operation, has adeptly bridged this gap for many projects. The eventual aim of this is to bring forth therapeutics that have the potential not only to treat but also to save lives.

What are some of the priorities that you’re currently working on?

Abzena is in an exciting phase of its growth trajectory, with expansion not only in terms of size but also in its capabilities. One of the primary focal points for us is the fusion of growth with efficiency. As we widen our footprint in the CDMO space, it becomes imperative to maintain and even enhance our operational effectiveness. This means that while we are scaling up to accommodate more projects and innovations, we are simultaneously implementing strategies to streamline our processes. By doing so, we aim to ensure that our delivery timelines, quality standards, and innovation remain uncompromised.

Another integral priority is ensuring the early stages of our customer projects are handled with utmost precision. This phase, which involves transitioning from an idea to a tangible product is critical. By ensuring the feasibility and safety of these projects, we set the stage for the subsequent steps, and it's a responsibility we take very seriously.

What has been the greatest benefit of being a BIA member?

Primarily, BIA offers us the opportunity to influence policy makers, ensuring that our perspectives and needs are appropriately represented and addressed in shaping policies for the UK  life sciences sector. Secondly, BIA delivers excellent networking opportunities, giving us access to industry leaders and experts. Through various events, conferences, and initiatives hosted by BIA, we have been provided with numerous opportunities to connect with peers, share ideas, and potentially forge beneficial collaborations.

What excites you about the UK life sciences sector?

The UK life sciences sector is a hub of innovation and cutting-edge research. What genuinely excites me is the sector's dynamism and its continual drive to push boundaries. The presence of world-renowned academic institutions and their synergies with startups and established pharmaceutical giants creates a foundation for groundbreaking discoveries and advancements. The sheer diversity of projects – ranging from bio-conjugates to new drug modalities – is a testament to the sector's vast potential and its readiness to address the multifaceted challenges of modern medicine.

If you could invite any scientist or entrepreneur to dinner, who would it be and why?

If I had the opportunity to invite any scientist or entrepreneur to dinner, I wouldn't necessarily choose the most renowned or historically significant figures. My interest lies in the future of science and the potential it holds. With that in mind, I'd opt for the young, brilliant minds making waves today. I would be particularly interested in inviting several individuals from the TIME 30 Under 30 list, those who are spearheading innovations and breaking barriers in the realms of science, medicine, and technology. While the past has provided us with invaluable lessons and incredible advancements, it's the thinkers of today and tomorrow who will shape our world in the years to come. Having a conversation with these up-and-coming innovators would undoubtedly be incredibly enlightening.

More about Nicole Wakes

The Cell Line Development division, under Nicole's leadership, plays a pivotal role in the biopharmaceutical chain within Abzena. The team, under her guidance, employs state-of-the-art technologies and methodologies to develop and optimize, therapeutic manufacturing cell lines, for scale-up, that are both robust and stable.

Nicole is now poised to transition and take the helm of all scientific operations at Abzena's Cambridge site. This new leadership role presents her with the exhilarating challenge of aligning diverse scientific sectors, optimizing workflows, and reinforcing Abzena's position as a key organisation for companies wishing to partner with a Contract Development and Manufacturing Organisation (CDMO).

Nicole's association with Abzena spans over a decade. During this time, she has witnessed and contributed to the company's growth, evolution, and its unwavering pursuit of scientific distinction. Before her time at Abzena, Nicole was an integral part of the research initiatives at Argenta Discovery. Preceding this engagement, she devoted approximately 16 years to GSK, refining her expertise as a Principal Scientist, where she made significant inroads in drug discovery and developmental processes.

 

More news and updates 

CEO Update - 10 June 2024

UK General Election and what it might mean for the industry, including Labour's pledges on Brexit and business taxes. Upcoming events including the Cambridge Wide Open Day and the Life Science Leadership Summit. UK tech companies pitching at the London Stock Exchange and Amber Therapeutics securing $100 million in funding.

Women in Biotech Mentoring Programme: Dr Carolina Grandellis

In this interview, Dr Carolina Grandellis, Lead of the Earlham Institute Biofoundry, explores the profound impact of the BIA's Women in Biotech mentoring programme on her professional and personal life.

An urgent call for technical standards and metrics for engineering biology

There are currently very few technical standards and metrics that are specific and appropriate to the field of engineering biology. Across the innovation pipeline, there are opportunities for standards to support faster development and enable accelerated commercialisation of the bioeconomy. In response to this, an effort was undertaken with the objective of identifying key areas where standards and metrics would enable the growth of the global bioeconomy.

CEO Update - 3 June 2024

MSD Merck acquire UK biotech EyeBio for $1.3 billion upfront, ASCO and BIO conference week and the UK General election campaign produces little news for the life science sector.

CEO Update - 28 May 2024

The UK General Election has been called for Thursday, 4 July. In practical terms, this means the end of the legislative pathway for many proposals as Parliament shuts down. Keep reading for updates on our general election webinars and UK events at BIO 2024.

CEO Update - 20 May 2024

The UK continues to lead the global discussion on tackling the antibiotic emergency. Last week saw leading global figures convene at the Royal Society to pledge money and agree actions on the AMR agenda.

Spotlight on hearing therapeutics landscape: a clinical perspective

Professor Gerard O’Donoghue shares his perspective as Consultant Neurotologist at Nottingham University Hospitals NHS Trust on why he believes that the development of new treatments and their subsequent clinical adoption are vital for people living with hearing loss.

Deep Biotech companies using engineering biology for good: Epoch Biodesign case study

Featured in BIA's Deep Biotech report, Epoch Biodesign aims to revolutionize plastic waste management by creating tailor-made enzymes that efficiently depolymerize a wide range of plastics into recyclable materials, offering a circular solution to tackle plastic pollution and promote sustainability.

Women in Biotech Mentoring Programme: Helen and Kathryn's experience

In this interview, consultant and best-selling author Kathryn Simpson, together with patent attorney Helen Bartlett, dive into their reasons for joining the BIA's Women in Biotech mentoring programme, and how this experience has impacted their professional and personal lives.

Deep Biotech companies using engineering biology for good: Solena Materials case study

Solena Materials is a pioneering biotech company spun out from Imperial College London, specialising in the development of computationally designed synthetic protein materials, originally featured in BIA's Deep Biotech report on disruptive innovation for global sustainability.

 

More within